Allosteric Modulators

 

Day 1 | Day 2 | Download Brochure | Download Allosteric Modulators Brochure 

Allosteric modulation of GPCRs is rapidly emerging as a major area of interest for pharmaceutical discovery because allosteric modulators have the potential to show dramatically improved safety, tolerance, and side-effect profiles compared to traditional orthosteric agonists and antagonists. The Allosteric Modulators meeting will focus on drug development efforts for discovering and optimizing allosteric modulators of medically relevant G Protein-Coupled Receptors (GPCRs).

TUESDAY, OCTOBER 2


Allosteric Modulators of CNS Targets

1:30 pm Chairperson’s Remarks

Andrew Alt, Ph.D., Senior Research Investigator, Lead Discovery, Bristol-Myers Squibb

1:40 Development of an Amino-aza-benzimidazolone Class of mGluR2 Positive Allosteric Modulators for the Treatment of Schizophrenia

Joseph Pero, Ph.D., Associate Principal Scientist, Medicinal Chemistry, Merck

Up-regulation of glutamatergic transmission in the forebrain has been associated with the symptomology of schizophrenia. Activation of the metabotropic glutamate receptor 2 (mGluR2) regulates glutamate hyperactivity and represents a novel approach toward the treatment of the disease. Positive allosteric modulators (potentiators) of mGluR2 may offer distinct advantages over orthosteric mGluR2/3 agonists due to their unique mode of action and selectivity. This talk will describe the discovery of a novel class of azabenzimidazolone-derived mGluR2 potentiators.

2:10 Challenges and Opportunities in the Development of Muscarinic Receptor Allosteric Modulators for Schizophrenia

Christian Felder, Ph.D., Research Scientist, Neuroscience, Eli Lilly & Co.

The development of allosteric modulators and agonists is beginning to solve the pharmacological selectivity challenge for small molecule development at highly homologous receptor families. Positive allosteric modulators (PAMs) have the added benefit of providing physiologic spatial and temporal regulation of natural neurotransmitter action. Though an innovative drug development opportunity, this approach is not without its challenges. Learnings will be discussed from the development of muscarinic small molecule discovery.

2:40 Interactions of Putative Endogenous Ligands with Metabotropic Glutamate (mGlu) Receptors in the Brain

Thomas E. Salt, Ph.D., Professor, Department of Visual Neuroscience, University College of London Institute of Ophthalmology

In addition to L-glutamate, other endogenous substances (some of which belong to the kynurenine metabolism pathway) have been proposed as ligands (“endocoids”) of mGlu receptors. Disorders of these pathways could thus result in changes in mGlu receptor function contributing to pathophysiology of CNS/neurological disorders such as sensory/pain processes, cognitive processes, schizophrenia, and epilepsy. We have been investigating the interactions of such endocoids with mGlu-mediated synaptic function and allosteric modulators in vivo and in vitro.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing


Allosterism by Design


» 3:45 KEYNOTE PRESENTATION: 

GPCR Allostery in the New Millennium: Lessons, Challenges and Opportunities

Arthur ChristopoulosArthur Christopoulos, Ph.D., Professor, Department of Pharmacology, Monash University

It is now well accepted that G protein-coupled receptors (GPCRs) possess allosteric binding sites. However, the myriad behaviors ascribed to allosteric ligands reflect not only molecular drug-receptor properties, but also cell-dependent factors that sculpt the final observed response. This presentation will focus on the minimal expectations of allosteric modulator effects and approaches for differentiating the contributions of the host system to observed allostery in order to facilitate modulator classification, structure-activity relations and translational studies.


4:45 Allosteric Modulators for Muscarinic Receptors

Andrew Tobin, Ph.D., Professor, Cell Physiology and Pharmacology, University of Leicester

5:15 Allosterism, Opioid Receptor Heteromers, and Antinociception

William P. Clarke, Ph.D., Professor, Department of Pharmacology, University of Texas Health Science Center

We present evidence, from primary cell culture and behavioral experiments, that delta and kappa opioid receptors form functional heterodimers in peripheral sensory neurons and that orthosteric ligands for one receptor of the pair allosterically regulate responses to ligands for the other receptor. Moreover, a heteromer-selective antibody against the delta-kappa heteromer also appears to allosterically regulate the response to orthosteric ligands. Some of this work has been recently published (see Berg et al, Mol Pharm 81(2):264-272, 2012).
 

5:45 End of Day



Day 1 | Day 2 | Download Brochure | Download Allosteric Modulators Brochure 




DOT Hub Icon 

2015 Discovery on Target Brochure  

2015 BROCHURE 


 PREMIER SPONSORS 

Cellecta 

Domainex

Molecular Sensing 

Rosa Drug Development Advisors

Sigma_NEW

 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


IPR_Micrombiome 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


 

September 21 

Next-Generation Histone Deacetylase Inhibitors Symposia 

Strategies for Rare Diseases Symposia 

September 22 

Developing CRISPR-Based Therapies Symposia 

September 22 - 23 

Targeting Epigenetic Readers and Chromatin Remodelers 

Targeting the Ubiquitin Proteasome System 

Targeting the Microbiome 

GPCR - Based Drug Discovery - Part 1 

Antibodies Against Membrane Protein Targets - Part 1 

RNAi for Functional Genomics Screening 

Gene Therapy Breakthroughs 

Targeting Ocular Disorders 

September 23 - 24 

Targeting Histone Methyltransferases and Demethylases 

Targeting the Unfolded Protein Response 

Kinase Inhibitor Discovery 

GPCR-Based Drug Discovery - Part 2 

Antibodies Against Membrane Protein Targets - Part 2 

New Frontiers in Gene Editing 

Quantitative Systems Pharmacology 

Short Courses 

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates 

SC2: Leveraging Data and Analytics for Drug DiSCovery 

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation 

SC4: Phenotypic SCreening and Chemical Probe Development 

SC5: GPCR Structure-based Drug Discovery 

SC6: Targeting of GPCRs with Monoclonal Antibodies 

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures 

SC8: Targeting Protein-protein Interactions: Biophysical Approaches 

SC9: Preclinical Animal Models for Ocular Indications 

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs 

SC11: Introduction to Targeted Covalent Inhibitors 

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors 

SC13: Gamification and Drug Target Challenges 

SC14: A Primer to Gene Editing: Tools and Applications 

SC15: Using Mechanistic Physiological Models In Drug Development